Navigation Links
Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor
Date:5/8/2008

Dana-Farber and Colorado Treating Patients with ENMD-2076

ROCKVILLE, Md., May 8 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that Dana-Farber Cancer Institute has joined the University of Colorado Cancer Center in conducting a Phase 1 study of ENMD-2076 in advanced cancer patients. Dr. Geoffrey Shapiro, Dana-Farber Cancer Institute, and Dr. Wells Messersmith, University of Colorado Cancer Center, will serve as co-principal investigators for the study.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Safety and tolerability of orally administered ENMD-2076 in refractory cancer patients will be assessed in this Phase 1 study. A secondary objective for the study will be to determine a dose-dependent response to treatment with ENMD-2076 through the evaluation of pharmacokinetic parameters.

ENMD-2076 is a novel, selective kinase inhibitor with potent activity against Aurora A and tyrosine kinases linked to the promotion of cancer and inflammatory diseases. ENMD-2076 acts through multiple pathways, resulting in both antiproliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated substantial, dose-dependent efficacy as a single agent in multiple preclinical models, including tumor regression in breast, colon, and leukemia models. Importantly, ENMD-2076 is an oral agent that has shown an acceptable toxicity profile in preclinical studies without cardiovascular toxicity.

Carolyn F. Sidor, MD, MBA, EntreMed Vice President and Chief Medical Officer commented on the study, "Both clinical trial sites are now enrolling and treating patients with our selective kinase inhibitor. We believe that this product candidate has substantial potential as both a single agent and in
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... , ... July 03, 2015 ... ... providing industry-leading products for use in applications such as animal waste reduction, ... treatment plants and restaurant kitchen settings, announced today that it will be ...
(Date:7/3/2015)... July 3, 2015 ... verkossa osoitteessa  http://www.openinnovationinscience.at Wienissä ... in Science" -jatkokoulutusohjelmaan 22.7.2015 asti.  ... (LBG) tekemän, kansainvälisiä tutkijoita ja ... kaksi suurinta haastetta ovat kannustimien ...
(Date:7/3/2015)... ... 03, 2015 , ... The Alexander Group, a 30-year old, ... alike-- typically known for its consummate professionalism-- embarks each year in a whacky ... from their day jobs. , "Our motto has always been work hard play ...
(Date:7/3/2015)... ... July 03, 2015 , ... The global failure analysis market is expected to ... The bioscience market is expected to grow at the highest CAGR of 8.46%; its ... in the research labs and academic institutions for root cause analysis of failure. The ...
Breaking Biology Technology:DryLet to Highlight Benefits of Patented ManureMagic™ at North American Manure Expo in Chambersburg, PA July 14-15, 2015 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3The Alexander Group Declares Their Independence with a Bit of Levity 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5
... Phase 3 CAPACITY Program - ... rate in CAPACITY -, BRISBANE, Calif., Oct. 16 ... 16, 2008, the Japanese,Ministry of Health, Labor and Welfare (MHLW) ... Ltd. to market pirfenidone,for the treatment of patients with idiopathic ...
... leading center for medical excellence; collaboration will focus on ... biomaterials and medical ... from the John S.,and James L. Knight Foundation, five leading medical ... -- a unique collaboration that will expand upon the region,s rich,legacy ...
... ISTO Technologies, Inc., a privately,held orthobiologics company, today ... cell-based therapy for spinal disc,repair. The data was ... of the North American Spine Society. Studies carried ... Department of Orthopedics,were designed to investigate potential applications ...
Cached Biology Technology:InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 2InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 3InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 4BioInnovation Institute in Akron Launched 2BioInnovation Institute in Akron Launched 3BioInnovation Institute in Akron Launched 4Positive Preclinical Data on Cell Therapy for Spinal Disc Repair Presented at 23rd Annual Meeting of the North American Spine Society 2
(Date:6/24/2015)... NEW YORK , June 24, 2015 ... favorable rate. The major drivers for the market include ... increasing number of new drug launches. Over the years, ... has increased. Between 2001 and 2010, the FDA approved ... addition, according to WIPO, Europe ...
(Date:6/24/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that Sharp has selected its industry-leading Natural ... its latest flagship smartphone device, the AQUOS ZETA ... shipments of its fingerprint ID sensor technology, this ... and leadership in the biometrics market through its ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... As it turns out, children were not the only ones ... this past holiday season. In a new research report published ... Leukocyte Biology ( http://www.jleukbio.org ), a team of scientists ... for Children show how a compound from licorice root (glycyrrhizin ...
... Hopkins University researchers have created biodegradable nanosized particles ... and viscous mucus secretions to deliver a sustained-release ... nanoparticles, which degrade over time into harmless components, ... suffering from dozens of health conditions, including diseases ...
... that a bacterial protein may help cocaine addicts break the ... that breaks down cocaine, thereby reducing its addictive properties. The ... of addiction has been limited by its short half-life in ... Journal of Pharmacology and Experimental Therapeutics and reviewed ...
Cached Biology News:A trip to the candy store might help ward off rare, but deadly infections 2Biodegradable particles can bypass mucus, release drugs over time 2Biodegradable particles can bypass mucus, release drugs over time 3
...
EoProbe Eosinophil Staining Kit, 1 Kit...
... kit contains the basic components required for ... natural and recombinant rat L-Selectin in cell ... contains sufficient materials to run ELISAs on ... following conditions are met: The ...
RABBIT ANTI PORCINE CARBOXYPEPTIDASE B...
Biology Products: